вЂњSince introducing the first battery-powered external pacemaker in 1957 to the innovative Micra leadless pacemaker portfolio, Medtronic continues to pioneer pacing innovations for physicians and their patients,вЂќ Medtronic CMO of the Cardiac Rhythm Management business Dr. Approval came on the back of data from the Marvel 2 study of the safety and effectiveness of accelerometer-based atrial sensing algorithms. Micra AV uses several algorithms to detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium and provide AV-synchronous pacing therapy to patients with AV block. Medtronic said the Micra TPS is the first-ever leadless pacemaker, with the original Micra VR version approved in Japan in 2017 for patients who only require single-chamber pacing.

Medtronic plans to launch the product in the country this month.ДЄccording to a news release, Micra AVвЂ™s indication covers the treatment of patients with AV (atrioventricular) block, a condition that impairs the electrical signals between the chambers of the heart (the atria and the ventricle).

JapanвЂ™s approval for the Micra AV transcatheter pacing system (TPS) covers the sale and reimbursement of the platform.

Medtronic (NYSE:MDT) announced that it received approval from JapanвЂ™s Ministry of Health, Labor and Welfare for its Micra AV system. The next-gen Micra AV is the size of a large vitamin pill -В the same as its predecessor.

Mdt nyse